The objective of the present study was to propose plasmalogens as a beneficial factor in human plasma by showing a highly positive correlation with high-density lipoprotein (HDL) and a significant reduction with aging. Methods: For 148 elderly subjects suspected of coronary artery disease (CAD), clinical characteristics such as coronary stenosis, hyperlipidemia, abnormal glucose tolerance, and hypertension were investigated, and serum biochemical markers including plasmalogens were determined. Results: Serum plasmalogens levels tended to fall in significant coronary stenosis and abnormal glucose tolerance. Correlative analyses among serum biochemical markers revealed that plasmalogens positively correlate with HDL-related values, particularly apolipoprotein A-(apo A-), and that the molar ratio of choline plasmalogen (ChoPlas) to ethanolamine plasmalogen (EtnPlas) correlates positively with low-density lipoprotein (LDL) particle size, and negatively with apo A-and fasting triglyceride (TG) levels. Comparison of plasmalogens in elderly subjects with those of 119 healthy young subjects showed a marked decrease in serum plasmalogens levels by aging. Conclusion: These results suggest that serum plasmalogens, antioxidant phospholipids, function as a beneficial factor as well as HDL, and that the measurement of serum plasmalogens is useful in clinical diagnosis.
Introduction
Plasmalogens (1-alkenyl-2-acyl-sn-glycero-3-phospholipids) are glycerophospholipids with vinyl ether bonds (-CH2-O-CH CH-) at the sn-1 position of the glycerol backbone, and are widely distributed in human and animals. Plasmalogens in serum are biosynthesized in liver and secreted to circulating blood as lipoproteins components. The distribution of plasmalogens is approximately equal throughout all lipoprotein density fractions in human plasma 1, 2) . Plasmalogens in serum are mainly classified into two types of glyc-erophospholipids such as ethanolamine plasmalogen (EtnPlas) and choline plasmalogen (ChoPlas), in which the former is a precursor of the latter in biosynthesis. Plasmalogen concentration in human serum is approximately 0.1-0.3 mM with the content ratio of ChoPlas to EtnPlas ranging from 0.5 to 1.5.
The physiological roles of serum plasmalogens are still obscure. A probable role is considered as defense against lipoprotein oxidation as an endogenous antioxidant from the following findings: i) a substantial proportion of plasmalogens biosynthesized in the liver is incorporated into lipoproteins as a constituent 3) , ii) the enol ether (vinyl ether) moiety of alkenyl chains of plasmalogen has the ability to scavenge oxygen radicals 4) , iii) the importance of plasmalogen in protecting cells from oxidative stress is verified by using mutant cells defective in the biosynthesis of plasmalogens 5, 6) , iv) enrichment of lipoproteins as well as liposomal membranes with plasmalogens increases their oxidative resistance 7, 8) . However, there have been few clinical data providing strong and clear evidence that supports the physiological significance of serum plasmalogens, probably because of the difficulty in measuring a small amount of plasmalogens in serum. There are only a few papers describing a decrease in serum plasmalogens with donor age and in hyperlipidemia 9, 10) . Fortunately, we have recently developed a highly sensitive and convenient method to determine plasmalogens 11) , which allows the rapid measurement of many serum samples. By using the new method, the effects of clinical status on serum plasmalogens and the correlation of plasmalogens with other serum biochemical markers were investigated in the present clinical study.
Subjects and Methods

Study Subjects
Elderly subjects (N 148; 110 male and 38 female) were consecutively referred for coronary angiography (CAG) to evaluate suspected coronary artery disease (CAD) at Teikyo University Hospital, but those receiving drug treatment for hyperlipidemia or diabetes mellitus were excluded. Healthy young subjects (N 119, 91 male and 28 female) were medical students at Teikyo University School of Medicine. Both subject groups were recruited to the study withr their informed consent. Elderly subjects were investigated for their clinical status such as coronary stenosis, hyperlipidemia (fasting TG 150 mg/L and/or TC 220 mg/L), abnormal glucose tolerance (S0' 126 and/or S120' 200 mg/dL), hypertension, and current cigarette smoking. Elderly subjects were further divided into two groups: CAD group had significantly coronary stenosis (more than 75% stenosis by CAG) including acute coronary syndrome patients, and a control group without coronary stenosis (less than 50% stenosis). To reveal the difference between the two groups, patients who had moderate coronary stenosis (50% stenosis 75%) were excluded from analysis. Elderly subjects were referred for oral glucose tolerance test (OGTT), and blood was drawn before and 2 h after 75 g glucose load. To avoid the influence of diabetes mellitus on analysis, subjects who showed a high HbA1c value (more than 6.0%) were also excluded from analysis. Venous blood samples were collected after at least 12-hour over-night fasting for the measurement of biochemical markers. Serum was separated by centrifugation, lipids and lipoproteins were analyzed immediately, and part of the serum was stored at 80 until analyzed.
Measurement of Plasmalogens and Phospholipids
Plasmalogen concentrations in serum were measured by high-performance liquid chromatography (HPLC) with radioactive iodine ( 125 I3 ), as described elsewhere 11) . In brief, total lipids were extracted from human serum by the Bligh & Dyer method 12) , re-dissolved in methanol, and then passed through a 0.2 m filter to remove insoluble deposits. The methanol-soluble fraction including phospholipids was reacted with a radioactive iodine reagent containing 125 I3 , which specifically and quantitatively binds to vinyl ether bonds of plasmalogens. An aliquot of the reaction mixtures was applied into HPLC equipped with a Diol column (Merck) , and eluted with acetonitrile/water. Elutions were fractionated, and the radioactivity of each fraction was counted with an auto-well -counter to measure the amounts of choline plasmalogen (ChoPlas) and ethanolamine plasmalogen (EtnPlas), respectively. Phospholipids concentration was determined by measuring the phosphorus content according to the procedure described by Chalvardjian et al. 13) .
Footnote: The use of the Diol column from GL Sciences is mentioned in the original paper 11) , but it was found later in a comparative experiment that the Diol column from Merck is useful in assessing the molar ratio of ChoPlas to EtnPlas more accurately.
Measurement of Other Biochemical Markers
Low-density lipoprotein particle size (LDL size) was measured by gradient gel electrophoresis with 2-16% polyacrylamide gel according to the procedure described by Krauss et al. 14) . Serum total cholesterol (TC) and triglyceride (TG) concentrations were determined enzymatically, high-density lipoprotein-cholesterol (HDL-C) by precipitation procedures, and apolipoproteins (apo) A-, A-, B, C-, C-, and E concentrations by turbidimetric immunoassays. LDL-cholesterol (LDL-C) concentration was calculated using the formula of Friedewald 15) . Apo B-48 concentration was determined by a sandwich enzyme-linked immunosorbent assay (ELISA) with monoclonal antibody against apo B-48 C-terminal-specific decapeptide, as described elsewhere 16) . Remnant-like particle-cholesterol (RLP-C) was measured by immunosorbent procedure, malondialdehyde-modified LDL (MDA-LDL) by ELISA, lipoprotein (a) [LP(a)] by latex agglutination, and lipoprotein lipase (LPL) mass by enzyme immunoassay (EIA). Serum glucose concentrations before and after (120 min) oral glucose tolerance test (OGTT) (S0', S120') were determined enzymatically, immunoreactive insulin before and after (120 min)
OGTT (IRI0', IRI120') by EIA, homeostasis model assessment-insulin resistance (HOMA-IR) by calculation using the following formula:
IRI ( U/mL) fasting glucose (mg/dL) 405
and glycosylated hemoglobin (HbA1c) by HPLC.
Statistical Analyses
Values are given as the means standard deviations (SD). Student's t test was used to analyze differences between the two groups in each clinical item. Correlative analyses were performed using SPSS software.
Results
The clinical backgrounds and the biochemical data of 148 elderly-group subjects are summarized in Tables 1 and 2. The differences of plasmalogens, HDLrelated values, and LDL particle size between the two groups in each clinical item were assessed by Student's t-test. Apo A-level was higher in both hyperlipidemia and cigarette-smoking groups. LDL size was smaller in hyperlipidemia and HDL-C was significantly higher in hypertension. Choline plasmalogen (ChoPlas) concentration was 10% lower in CAD ( 75% stenosis) and ethanolamine plasmalogen (EtnPlas) concentration was 15% lower in abnormal glucose tolerance as compared to each control group, but not significantly (Table 3) .
Biochemical markers having significant correlation with plasmalogen-related values are shown in Table 4. It was found that plasmalogen levels significantly show positive correlations with HDL-related values, particularly apo A-, and negative correlation with HbA1c, one of the signs of abnormal glucose tolerance. Furthermore, the molar ratio of choline plasmalogen to ethanolamine plasmalogen (ChoPlas/EtnPlas ratio) significantly showed negative correlations with apo Aand fasting TG levels ( Table 4) . The biochemical markers showing high correlation (coefficient 0.4) with LDL particle size are listed in Table 5 . It was confirmed as reported previously 17) that HDL-C positively correlates with LDL particle size, and that remnant lipoprotein-related values such as RLP-C and fasting TG negatively correlate with LDL size. In addition, it was found for the first Values are expressed as the mean SD and the number (n) of subjects. Abbreviations are referred to in the Methods section. time that the ChoPlas/EtnPlas ratio also positively correlates with LDL size (Table 5) . Plasmalogens concentrations in serum in elderly subjects were compared to those of healthy young subjects. Both types of plasmalogen (ChoPlas and EtnPlas) levels were approximately 40% lower in the serum of elderly subjects, but the ChoPlas/EtnPlas ratio was nearly the same in both subject groups( Table 6 ).
Discussion
The study subjects showed no relations of major known risk factors such as TC, LDL-C, HDL-C, RLP-C, TG, and LP (a) levels with coronary stenosis (data not shown). There were no significant differences in lipid parameters among the subjects, because patients receiving drug treatment for hyperlipidemia or diabetes mellitus were excluded. This may be one reason for there being no relation of HDL-C with coronary stenosis, although the reason is not clear.
It was found for the first time in the present study that plasmalogen levels in human serum show highly positive correlations with apolipoproteins (apo) Aand A-, the major protein constituents of HDL, as well as HDL-C ( Table 4) . It has been demonstrated using peroxisome proliferator-activated receptor alpha (PPAR ) agonists such as fibrates, hypolipidemic drugs, that apo A-production is regulated, at least partly, based on PPAR -mediated transcription 18) . PPAR is also involved in stimulating beta-oxidation of fatty acids in peroxisome 19) . On the other hand, plasmalogen biosynthesis is dependent on peroxisomal function as follows: i) the enzymes involved in the first two steps of plasmalogens biosynthesis, dihydroxyacetone phosphate acyltransferase (DHAPAT) and alkyl-DHAP synthase, are localized in peroxisome, ii) fatty alcohol, which is utilized to synthesize alkenyl chains of plasmalogens, is mainly de novo-synthesized from acetylCoA generated from peroxisomal beta-oxidation 20) . It is reported that both plasmalogens synthesis and verylong-chain fatty acid beta-oxidation are accelerated by increasing the number of peroxisomes with peroxisome proliferators such as fibrate derivative 21) and 4-phenylbutyrate 22) . Therefore, although it is unknown whether plasmalogen synthesis is directly regulated by PPAR as well as apo A-production, it is expected that plasmalogen biosynthesis may be closely linked with apo A-production through peroxisomal function. It is reported using plasmalogen-deficient cells that plasmalogens are required for the process of HDL-mediated cellular cholesterol efflux 23) . Furthermore, ethanolamine plasmalogen (EtnPlas) was demonstrated by us to reduce the susceptibility of cholesterol in membranes 24) to oxidation caused by free radicals. These findings suggest that the significant correlation between plasmalogens and HDL may be partly explained by the physiological roles of plasmalogens in preventing cholesterol oxidation and facilitating cellular cholesterol efflux mediated by HDL.
In addition to hyperlipidemia (Table 3) , low HDL-C level, and high remnant lipoprotein-related values such as fasting TG (Table 5) , it was found for the first time that the molar ratio of choline plasmalogen to ethanolamine plasmalogen (ChoPlas/EtnPlas ratio) in serum significantly correlates with LDL particle size. Furthermore, the ChoPlas/EtnPlas ratio also negatively correlated with apo A-and fasting TG levels. As EtnPlas is a precursor of ChoPlas in biosynthesis 25) , the ChoPlas/EtnPlas ratio can be regarded as a value reflecting the transfer rate from EtnPlas to ChoPlas; therefore, the cause or effect of the declining transfer rate from EtnPlas to ChoPlas is assumed to be potentially related to the appearance of atherogenic small dense LDL, but it is unknown how plasmalogens are involved in the modification of lipoprotein metabolism.
It was confirmed as reported previously 10) that plasmalogen levels are reduced in human serum with donor age (Table 6 ). Although the marked decrease (40% reduction) is not only due to aging, a large proportion of the decrease appears to be responsible for aging by reason of a modest reduction by other clinical factors such as coronary stenosis or abnormal glucose tolerance observed among elderly subjects ( Table  3) . It is known that aging decreases the expression of PPAR and induces redox imbalance (predisposition to oxidative status), and that PPAR agonists elevate the transcript levels of PPAR and restore redox balance 26, 27) . These results suggest that the decrease in plasmalogen levels in blood (serum and red cell membranes) with aging is probably caused by reducing the number and/or function of peroxisome in liver, as represented by the expression of PPAR , and the lack of plasmalogens, antioxidant phospholipids, is partly responsible for the oxidative status by aging.
Conclusion
Serum plasmalogens levels show a significant positive correlation with HDL, a substantial decrease with aging, and modest reductions by significant coronary stenosis ( 75% stenosis) and abnormal glucose tolerance. The ChoPlas/EtnPlas ratio correlates positively with LDL particle size, and negatively with apo Aand fasting TG levels. These results suggest that plasmalogens, antioxidant phospholipids, act as a beneficial factor as well as HDL in human plasma, and are potentially related to the appearance of atherogenic small dense LDL.
